Stockscreener 앱 받기
0.279
3.12%
-0.009
시간 외 거래:
.29
0.011
+3.94%
전일 마감가:
$0.288
열려 있는:
$0.3
하루 거래량:
94,365
Relative Volume:
0.47
시가총액:
$11.48M
수익:
-
순이익/손실:
$-117.67M
주가수익비율:
-0.0903
EPS:
-3.09
순현금흐름:
$-101.06M
1주 성능:
-5.10%
1개월 성능:
+11.60%
6개월 성능:
-62.80%
1년 성능:
-85.77%
1일 변동 폭
$0.2743
$0.30
1주일 범위
$0.2712
$0.30
52주 변동 폭
$0.2195
$3.67
Athira Pharma Inc Stock (ATHA) Company Profile
명칭
Athira Pharma Inc
전화
(425) 620-8501
주소
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
ATHA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATHA
Athira Pharma Inc
|
0.279 | 11.48M | 0 | -117.67M | -101.06M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-19 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-09-04 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-09-04 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-09-04 | 다운그레이드 | Rodman & Renshaw | Buy → Neutral |
| 2024-08-19 | 개시 | Rodman & Renshaw | Buy |
| 2022-10-17 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-06-23 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-06-23 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-06-23 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-05-10 | 개시 | BTIG Research | Buy |
| 2022-04-21 | 개시 | Berenberg | Buy |
| 2021-12-15 | 개시 | Goldman | Neutral |
| 2020-10-13 | 개시 | Goldman | Buy |
| 2020-10-13 | 개시 | JMP Securities | Mkt Outperform |
| 2020-10-13 | 개시 | Jefferies | Buy |
| 2020-10-13 | 개시 | Stifel | Buy |
모두보기
Athira Pharma Inc 주식(ATHA)의 최신 뉴스
ATHAAthira Pharma, Inc. Latest Stock News & Market Updates - Stock Titan
Athira Pharma shifts to Nasdaq Capital Market amid compliance bid By Investing.com - Investing.com Canada
Athira Pharma shifts to Nasdaq Capital Market amid compliance bid - Investing.com Australia
Athira Pharma stock plunges to 52-week low of $0.25 - Investing.com Australia
Athira Pharma stock plunges to 52-week low of $0.25 By Investing.com - Investing.com South Africa
SEC Form PRE 14A filed by Athira Pharma Inc. - Quantisnow
Athira Pharma stock hits 52-week low at $0.3 amid steep decline - Investing.com India
Athira Pharma stock hits 52-week low at $0.3 amid steep decline By Investing.com - Investing.com South Africa
What is ATHA’s price-to-sales ratio telling us about the company’s value? - US Post News
Athira Pharma: Hold Rating Amid Strategic Uncertainty and Resource Challenges - TipRanks
Athira Pharma stock hits 52-week low at $0.33 amid steep decline - Investing.com India
Athira Pharma stock hits 52-week low at $0.33 amid steep decline By Investing.com - Investing.com South Africa
Athira Pharma Stock Price, Quotes and Forecasts | NASDAQ:ATHA - Benzinga
Athira Pharma’s Strategic Focus on ATH-1105 Amidst Uncertainties: Hold Rating Maintained - TipRanks
Athira Pharma’s 2024 Financial Results and Pipeline Progress - MSN
Athira Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates - GlobeNewswire
Athira Pharma, Inc. SEC 10-K Report - TradingView
Athira Pharma stock hits 52-week low at $0.41 amid steep decline - Investing.com Australia
Athira Pharma stock hits 52-week low at $0.41 amid steep decline By Investing.com - Investing.com South Africa
Athira Pharma Inc expected to post a loss of 44 cents a shareEarnings Preview - TradingView
Can This Former Amgen VP Transform Terns Pharmaceuticals as New CFO? - Stock Titan
ATHA INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Athira Pharma, Inc. - Marketscreener.com
Molecular Partners (NASDAQ:MOLN) versus Athira Pharma (NASDAQ:ATHA) Head to Head Review - Defense World
Athira Pharma (ATHA) Expected to Announce Earnings on Thursday - Defense World
Alterity stock jumps on data for lead drug (ATHA:NASDAQ) - Seeking Alpha
Can Athira Pharma (NASDAQ:ATHA) Afford To Invest In Growth? - Yahoo Finance
Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct - MSN
Insider Buyers Lose Additional US$78k As Athira Pharma Dips To US$21m - Simply Wall St
Keeping Fraud Out of Research: Government Grant Whistleblower Awarded Over $200,000 - The National Law Review
Will Athira Pharma See A Boost From LIFT-AD Trial Results In Alzheimer's Research? - RTTNews
Alzheimer’s Drugmaker Athira Shells Out $4 Million In DOJ Settlement - Being Patient
Athira to pay $4M to resolve research misconduct allegations - BioWorld Online
ATHA Stock Earnings: Athira Pharma Beats EPS for Q2 2024 - MSN
Whistleblower Receives $200K After Alleging Scientific Research Misconduct - Whistleblower Network News
Bothell's Athira Pharma to pay $4M to settle falsified research claims - The Business Journals
Biotech company agrees to pay $4 million to settle data falsification allegations - Retraction Watch
Athira Inks $4M FCA Deal Over Ex-CEO's Research Fraud - Law360
Athira Pharma Inc. Agrees to Pay $4M to Settle False Claims Act Allegations Related to Scientific Research - U.S. Politics Today
Athira Pharma to Pay $4 Million Over Alleged Research Misconduct - Marketscreener.com
Bothell pharma company to pay $4 million over falsified research claims - MSN
Athira Pharma Settles Claims of NIH Research Grant Misconduct - Bloomberg Law
Athira Pharma CEO sells shares worth $14,107 By Investing.com - Investing.com South Africa
Athira Pharma Inc (ATHA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):